Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease

Abstract Alzheimer’s disease (AD) is the most common neurodegenerative disorder, affecting millions worldwide. The clinical presentation of AD is heterogenous and often complicated by the presence of multiple co-pathologies, which can overlap with features of other neurodegenerative disorders, underscoring the need for tools to aid accurate and timely diagnosis. Biomarkers for AD span multiple modalities and are being increasingly used in clinical settings to aid diagnosis, monitor disease progression, and assess eligibility and response to disease-modifying therapies. Here, we provide an overview of current clinical applications of fluid, imaging, and digital biomarkers for AD. We also discuss biomarkers under development and challenges associated with the implementation of these modalities in clinical settings.

Authors

Institutions

Publication Details

Journal
Alzheimer s Research & Therapy
Published
2026-01-09
DOI
https://doi.org/10.1186/s13195-025-01921-5
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease

Ayesha Fawad, Zampeta-Sofia Alexopoulou, Sandar Aye, Shirine Moukaled et al.
Alzheimer s Research & Therapy
Dementia and Cognitive Impairment Research
article

Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease

Ayesha Fawad, Zampeta-Sofia Alexopoulou, Sandar Aye, Shirine Moukaled, Prithvi Arunachalam, Aram Aslanyan, Ross W. Paterson, Ana Sabsil López Rocha, Monica Crugel, Claudia Tato-Fernández, Stamatia Karagianni, Aitana Sogorb-Esteve, Michael Schöll, Alexandra König, Julia R. Bacci
article en

Abstract

Abstract Alzheimer’s disease (AD) is the most common neurodegenerative disorder, affecting millions worldwide. The clinical presentation of AD is heterogenous and often complicated by the presence of multiple co-pathologies, which can overlap with features of other neurodegenerative disorders, underscoring the need for tools to aid accurate and timely diagnosis. Biomarkers for AD span multiple modalities and are being increasingly used in clinical settings to aid diagnosis, monitor disease progression, and assess eligibility and response to disease-modifying therapies. Here, we provide an overview of current clinical applications of fluid, imaging, and digital biomarkers for AD. We also discuss biomarkers under development and challenges associated with the implementation of these modalities in clinical settings.

Alzheimer s Research & TherapyVol. 18(1)
Tulane University (US), Oxleas NHS Foundation Trust (GB), University of Turku (FI), Lund University (SE), Université Côte d'Azur (FR), Sahlgrenska University Hospital (SE), Turku University Hospital (FI), Karolinska Institutet (SE), Centre Hospitalier Universitaire de Nice (FR), Turku PET Centre (FI), Amsterdam Neuroscience (NL), UK Dementia Research Institute (GB), MRC Prion Unit (GB), Cognition Behaviour Technology (FR), National Hospital for Neurology and Neurosurgery (GB), University College London (GB), Wake Forest University (US), Vrije Universiteit Amsterdam (NL), University of Gothenburg (SE)
Openalex Percentile: Top 92%
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.